ALTRAVAX, INC.

Address

3233 15TH ST S
FARGO, ND, -

Information

DUNS: 832765932
# of Employees: 0

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Development of a Universal Influenza B Vaccine

    Amount: $600,000.00

    DESCRIPTION provided by applicant Influenza is associated with deaths in the US each year and vaccination is the best strategy for the prevention of influenza A major obstacle to the ...

    SBIRPhase I2015Department of Health and Human Services
  2. A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus

    Amount: $532,838.00

    DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of d ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
  3. Novel Subunit Vaccines against Varicella Zoster Virus

    Amount: $597,176.00

    DESCRIPTION provided by applicant Varicella zoster virus VZV is a neurotropic alpha herpesvirus that causes varicella chickenpox and establishes latency in the sensory ganglia Reactivation of ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  4. Novel Tetravalent Vaccines for Dengue Virus

    Amount: $598,472.00

    DESCRIPTION (provided by applicant): Dengue virus infection is an emerging disease and an expanding global health problem. More than one-third of the world's population is at risk for transmissio ...

    SBIRPhase I2012Department of Health and Human Services
  5. Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Vaccines are urgently needed to slow the spread of the HIV/AIDS epidemic, and immunogens that can induce neutralizing antibodies remain an important goal of vaccin ...

    SBIRPhase I2012Department of Health and Human Services
  6. Novel Therapeutic Vaccines for Chronic HBV

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a noncytopathic, hepatotropic DNA virus that results in a self-limited acute infection in a majority of otherwise healthy individuals bu ...

    SBIRPhase I2012Department of Health and Human Services
  7. VLP-Based Antibody-Inducing Vaccines for HIV-1

    Amount: $599,688.00

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV- ...

    SBIRPhase I2010Department of Health and Human Services
  8. Improved Vaccines for Influenza B Virus

    Amount: $598,391.00

    DESCRIPTION (provided by applicant): Influenza is a major cause of morbidity and mortality around the world. In the United States, seasonal epidemics of flu occur from late fall to early spring affec ...

    SBIRPhase I2010Department of Health and Human Services
  9. Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates

    Amount: $599,074.00

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV- ...

    SBIRPhase I2010Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government